| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael P Caligiuri, Hans-Leo Teulings, Charles E Dean, Alexander B Niculescu, James Loh. Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. Human movement science. vol 28. issue 5. 2010-01-08. PMID:19692133. |
twenty-seven schizophrenia patients treated with risperidone, six schizophrenia patients who received no antipsychotic medication and 47 healthy comparison participants were enrolled. |
2010-01-08 |
2023-08-12 |
human |
| Jesús De la Gándara, Luis San Molina, Gabriel Rubio, Alexander Rodriguez-Morales, Rebeca Hidalgo Borrajo, José Antonio Buró. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. Expert review of neurotherapeutics. vol 9. issue 10. 2009-12-23. PMID:19831836. |
experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the sphere study. |
2009-12-23 |
2023-08-12 |
Not clear |
| Alessandro Rossi, Anna Bagalà, Vincenzo Del Curatolo, Francesco Scapati, Micaela Maria Bernareggi, Maria Grazia Giustr. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Human psychopharmacology. vol 24. issue 7. 2009-12-09. PMID:19790173. |
remission in schizophrenia: one-year italian prospective study of risperidone long-acting injectable (rlai) in patients with schizophrenia or schizoaffective disorder. |
2009-12-09 |
2023-08-12 |
Not clear |
| Alessandro Rossi, Anna Bagalà, Vincenzo Del Curatolo, Francesco Scapati, Micaela Maria Bernareggi, Maria Grazia Giustr. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Human psychopharmacology. vol 24. issue 7. 2009-12-09. PMID:19790173. |
to evaluate the maintenance of efficacy of risperidone long-acting injectable (rlai) in stable patients with schizophrenia or schizoaffective disorders. |
2009-12-09 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Seung-Hyun Lee, Yo-Han Lee, Su-Jin Yang, Jin-Sang Yoo. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Human psychopharmacology. vol 24. issue 7. 2009-12-09. PMID:19790174. |
effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. |
2009-12-09 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Seung-Hyun Lee, Yo-Han Lee, Su-Jin Yang, Jin-Sang Yoo. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Human psychopharmacology. vol 24. issue 7. 2009-12-09. PMID:19790174. |
to investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (aaps) to long-acting injectable risperidone (lair) in patients with schizophrenia. |
2009-12-09 |
2023-08-12 |
Not clear |
| Jing Cheng, Gaohua Wang, Ling Xiao, Huiling Wang, Xiaoping Wang, Chengyan L. Electro-acupuncture versus sham electro-acupuncture for auditory hallucinations in patients with schizophrenia: a randomized controlled trial. Clinical rehabilitation. vol 23. issue 7. 2009-12-02. PMID:19470551. |
to compare the efficacy of electro-acupuncture with that of sham electro-acupuncture for auditory hallucinations in patients with schizophrenia partially responsive or non-responsive to risperidone. |
2009-12-02 |
2023-08-12 |
Not clear |
| Hiroshi Ito, Harumasa Takano, Hidehiko Takahashi, Ryosuke Arakawa, Michie Miyoshi, Fumitoshi Kodaka, Masaki Okumura, Tatsui Otsuka, Tetsuya Suhar. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 29. issue 43. 2009-12-02. PMID:19864585. |
the therapeutic effects of risperidone in schizophrenia might be related to such stabilizing effects on dopaminergic neurotransmission responsivity. |
2009-12-02 |
2023-08-12 |
human |
| B A Fijal, B J Kinon, S Kapur, V L Stauffer, R R Conley, H H Jamal, J M Kane, M M Witte, J P Housto. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. The pharmacogenomics journal. vol 9. issue 5. 2009-12-01. PMID:19451915. |
candidate-gene association analysis of response to risperidone in african-american and white patients with schizophrenia. |
2009-12-01 |
2023-08-12 |
Not clear |
| J M Olivares, J Peuskens, J Pecenak, S Resseler, A Jacobs, K S Akhra. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Current medical research and opinion. vol 25. issue 9. 2009-11-24. PMID:19604073. |
clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. |
2009-11-24 |
2023-08-12 |
Not clear |
| Shahu Ingole, N R Belorkar, Praveer Waradkar, Meena Shrivastav. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients. Indian journal of physiology and pharmacology. vol 53. issue 1. 2009-11-24. PMID:19810576. |
among 60 newly diagnosed dsm-iv patients of schizophrenia enrolled, it was observed that mean body weight & bmi were significantly increased from baseline to 6 & 12 weeks in both olanzapine (n = 30) & risperidone groups (n = 30) (p < 0.001). |
2009-11-24 |
2023-08-12 |
Not clear |
| John M Kane, Christoph U Correll, Donald C Goff, Brian Kirkpatrick, Stephen R Marder, Estelle Vester-Blokland, Wei Sun, William H Carson, Andrei Pikalov, Sheila Assunção-Talbot. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry. vol 70. issue 10. 2009-11-23. PMID:19906340. |
a multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. |
2009-11-23 |
2023-08-12 |
Not clear |
| John M Kane, Christoph U Correll, Donald C Goff, Brian Kirkpatrick, Stephen R Marder, Estelle Vester-Blokland, Wei Sun, William H Carson, Andrei Pikalov, Sheila Assunção-Talbot. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry. vol 70. issue 10. 2009-11-23. PMID:19906340. |
this study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder. |
2009-11-23 |
2023-08-12 |
Not clear |
| Peter J Weiden, Nina R Schooler, Jeremy C Weedon, Abdel Elmouchtari, Ayako Sunakawa, Stephen M Goldfinge. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. The Journal of clinical psychiatry. vol 70. issue 10. 2009-11-23. PMID:19906343. |
a randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. |
2009-11-23 |
2023-08-12 |
Not clear |
| Peter J Weiden, Nina R Schooler, Jeremy C Weedon, Abdel Elmouchtari, Ayako Sunakawa, Stephen M Goldfinge. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. The Journal of clinical psychiatry. vol 70. issue 10. 2009-11-23. PMID:19906343. |
we report on acceptance and initial adherence outcomes with risperidone long-acting injection (rlai) in first-episode schizophrenia patients. |
2009-11-23 |
2023-08-12 |
Not clear |
| I Amado, M C Bourdel, C Daban, M F Poirier, H Loo, P Bouhours, M O Kreb. Preattentional processes and disorganization in schizophrenia: Influence of a 6-week risperidone treatment. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 7. 2009-11-17. PMID:19527763. |
preattentional processes and disorganization in schizophrenia: influence of a 6-week risperidone treatment. |
2009-11-17 |
2023-08-12 |
Not clear |
| Arjun Saxena, Jeffery Grace, Josie L Olympia, Eileen Trigoboff, Thomas Watson, Sharon Cushman, David Newcome. Risperidone long-acting injections: successful alternative deltoid muscle injections for refractory schizophrenia. Psychiatry (Edgmont (Pa. : Township)). vol 5. issue 9. 2009-11-10. PMID:19727259. |
risperidone long-acting injections: successful alternative deltoid muscle injections for refractory schizophrenia. |
2009-11-10 |
2023-08-12 |
Not clear |
| Arjun Saxena, Jeffery Grace, Josie L Olympia, Eileen Trigoboff, Thomas Watson, Sharon Cushman, David Newcome. Risperidone long-acting injections: successful alternative deltoid muscle injections for refractory schizophrenia. Psychiatry (Edgmont (Pa. : Township)). vol 5. issue 9. 2009-11-10. PMID:19727259. |
in this article, we present a case example of a 58-year-old male patient with paranoid schizophrenia who was treated with risperidone long-acting injection given into the deltoid muscle instead of the us food and drug administration (fda)-approved gluteal muscle injection site. |
2009-11-10 |
2023-08-12 |
Not clear |
| Shubhra Mace, David Taylo. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS drugs. vol 23. issue 9. 2009-11-09. PMID:19689167. |
aripiprazole is an atypical antipsychotic that has been shown to be more effective than placebo and at least as effective as haloperidol and risperidone in the treatment of schizophrenia and schizoaffective disorder. |
2009-11-09 |
2023-08-12 |
Not clear |
| Ying-Ching Lai, Ming-Chyi Huang, Chun-Hsin Chen, Chang-Jer Tsai, Chun-Hung Pan, Chih-Chiang Chi. Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. Psychiatry and clinical neurosciences. vol 63. issue 4. 2009-10-13. PMID:19457210. |
this 12-week open-label study was designed to investigate the pharmacokinetics and efficacy of a direct switch from a conventional depot to long-acting injectable risperidone in patients with schizophrenia and schizoaffective disorder. |
2009-10-13 |
2023-08-12 |
Not clear |